Market Data
Market Cap₹208.05 Cr.
52W High₹22.49
Current Price₹10.71
52W Low₹9.2
Down from 52W High52.4 %
Face Value₹1
Performance
ROCE-13.11 %
ROE-42.08 %
EPS (TTM)₹-0.79
EPS Prev Qtr₹-3.38
EPS Last Year₹-7.85
EBITDA Qtr₹-27.38 Cr.
Book Value₹30
Financial Health
Debt/Equity0
Debt/Profit0
Total Assets₹621.61 Cr.
Promoter Holding51.84 %
Earning Power-13.88 %
Valuation
Industry P/E33.81
Price to Book0.36
Price to Sales85.27
Key Metrics
__derived
1
Face Value
₹1
About Nectar Lifescience Ltd
Healthcare · Pharmaceuticals
Nectar Lifescience Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹208.05 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a majority promoter holding of 51.84%, indicating strong control and alignment of interests.
- The P/B ratio is 0.25, suggesting the stock may be undervalued relative to its book value.
Weaknesses
- The company reports a significant net loss of ₹-245.06 Cr, indicating severe financial distress.
- The P/E ratio of -1.07 reflects negative earnings, signaling poor profitability.
- ROCE is -4.96%, showing inefficient use of capital and operating losses.
- ROE is -25.63%, indicating substantial erosion of shareholder equity.
- Revenue of ₹2.44 Cr appears extremely low relative to the net loss, highlighting operational inefficiencies.
- A debt-to-equity ratio of 0.61 suggests notable leverage, increasing financial risk amid losses.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue fell 95.7% YoY, Profit grew 75.6% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 10.24 | 0.71 | 0 | 1.29 | 0.44 |
| ↳ QoQ Growth | - | -93.1% | -100.0% | - | -65.9% |
| Expenses | 12.57 | 0.28 | 1.99 | 58.61 | 27.82 |
| Operating Profit | -2.34 | 0.44 | -1.99 | -57.32 | -27.38 |
| OPM % | -22.85% | 61.97% | - | -4,443.41% | -6,222.73% |
| Other Income | 0.32 | 0.03 | 0.66 | 6.29 | 2.92 |
| Interest | 0 | 0 | 30.22 | 5.9 | 0.16 |
| Depreciation | 0.62 | 0.11 | 0.06 | 0.08 | 0.11 |
| EBITDA | -1.72 | 0.55 | -1.93 | -57.24 | -27.27 |
| EBITDA Margin % | -16.8% | 77.46% | - | -4,437.21% | -6,197.73% |
| Profit Before Tax | -2.01 | 0.46 | -31.55 | -56.93 | -24.62 |
| Tax % | 34.83% | 34.78% | 34.93% | 34.64% | 36.15% |
| Net Profit | -63.23 | -176.01 | 14.27 | -67.92 | -15.4 |
| ↳ QoQ Growth | - | -178.4% | +108.1% | -576.0% | +77.3% |
| EPS | -2.82 | -7.85 | 0.64 | -3.38 | -0.79 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 12.24 | 2.44 |
| Expenses | 73.45 | 88.7 |
| Operating Profit | -61.21 | -86.25 |
| OPM % | -500.08% | -3534.84% |
| Other Income | 7.3 | 9.9 |
| Interest | 36.12 | 36.28 |
| Depreciation | 0.87 | 0.36 |
| Profit Before Tax | -90.03 | -112.64 |
| Tax % | 34.74% | 35.05% |
| Net Profit | -292.89 | -245.06 |
| EPS | -13.41 | -11.38 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-27.14%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
-25.63%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 22.426 | 19.43 |
| Reserves | 933.681 | 562.87 |
| Borrowings | 582.02 | 0 |
| Other Liabilities | 509.1 | 39.31 |
| Total Liabilities | 2047.225 | 621.61 |
| Fixed Assets | 633.109 | 103.4 |
| CWIP | 56.728 | 0 |
| Investments | 0.77 | 13.21 |
| Other Assets | 1356.62 | 505 |
| Total Assets | 2047.225 | 621.61 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | 169.438 | -348.724 |
| Cash from Investing Activity | -41.931 | 1208.149 |
| Cash from Financing Activity | -128.091 | -766.512 |
| Net Cash Flow | -0.584 | 92.913 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 18536.57 |
| ROCE % | -9.85% |
Shareholding Pattern
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters % | 44.91% | 51.84% | 51.84% |
| FIIs % | 0.52% | 0.6% | 0.5% |
| DIIs % | 5.82% | 4.01% | 3.74% |
| Public % | 39.72% | 36.23% | 37.58% |
| No. of Shareholders | 78,124 | 74,834 | 73,834 |
Major Shareholders (>1%)
- Sanjiv GoyalPromoter and Promoter Group24.63%
- Sanjiv (huf) - Karta Sanjiv GoyalPromoter and Promoter Group22.46%
- Raman GoyalPromoter and Promoter Group4.76%
- Rajasthan Global Securities Private LimitedPublic Shareholding3.73%
As of 2026-06-30View all shareholders →